Methyl Alcohol

Methyl Alcohol

SCHEMBL449684

CO.CO.O.O

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO

The experimentally established mechanism targets of Methyl Alcohol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methyl Alcohol SCHEMBL44614 1.00
Methyl Alcohol SCHEMBL71617 1.00
Methyl Alcohol SCHEMBL9526155 1.00 TSHR (0.75)
Methyl Alcohol SCHEMBL9526147 1.00 TSHR (0.75)
Methyl Alcohol SCHEMBL15348234 1.00
Methyl Alcohol SCHEMBL44615 1.00
Methyl Alcohol SCHEMBL11649435 1.00
Methyl Alcohol SCHEMBL449756 1.00
Methyl Alcohol SCHEMBL321255 1.00 TSHR (0.75)
Methyl Alcohol SCHEMBL7862958 1.00 TSHR (0.75)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115873146-A Single crystal of sugammadex sodium and preparation method thereof 广东东阳光药业有限公司 2023-03-31 CN claimed
EP-4314193-A1 STABLE AIGS FILMS Shoei Chemical Inc. (JP) 2024-02-07 EP disclosed
CN-115873146-A Single crystal of sugammadex sodium and preparation method thereof 广东东阳光药业有限公司 2023-03-31 CN disclosed
EP-2509583-B1 PHARMACEUTICAL COMPOSITION COMPRISING OLIGOPEPTIDES, PREFERABLY CILENGITIDE MERCK PATENT GMBH (DE) 2019-05-15 EP disclosed
EP-3085704-A1 NOVEL SOLID MATERIALS OF {[(2S, 5R, 8S, 11S)-5-BENZYL-11-(3-GUANIDINO-PROPYL)-8-ISOPROPYL-7-METHYL-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAAZA-CYCLOPENTADEC-2-YL]-ACETIC ACID} AND METHODS FOR OBTAINING THEM Merck Patent GmbH (DE) 2016-10-26 EP disclosed
US-9433577-B2 Pharmaceutical composition comprising oligopeptides MERCK PATENT GMBH (DE) 2016-09-06 US disclosed
CN-102652015-B Pharmaceutical composition comprising oligopeptides, preferably cilengitide 默克专利有限公司 2016-08-03 CN disclosed
EP-2432801-B1 NOVEL SOLID MATERIALS OF {[2S, 5R,8S,11S)-5-BENZYL-11-(3-GUANIDINO-PROPYL)-8-ISOPROPYL-7-METHYL-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAAZA-CYCLOPENTADEC-2-YL]-ACETIC ACID} AND METHODS FOR OBTAINING THEM MERCK PATENT GMBH (DE) 2016-03-23 EP disclosed
CN-102428098-B Novel solid substances of { [ (2S,5R,8S,11S) -5-benzyl-11- (3-guanidino-propyl) -8-isopropyl-7-methyl-3, 6,9,12, 15-pentaoxo-1, 4,7,10, 13-pentaaza-cyclopentadecan-2-yl ] -acetic acid } and process for obtaining them MERCK PATENT GMBH 2014-11-05 CN disclosed
US-8765684-B2 Solid materials of {[(2S,5R,8S,11S)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid} and methods for obtaining them MERCK PATENT GMBH (DE) 2014-07-01 US disclosed
US-20140088022-A1 Novel Solid Materials of and Methods for Obtaining Them MERCK PATENT GMBH (DE) 2014-03-27 US disclosed
US-8586545-B2 Solid materials of {[(2S, 5R,8S,11S)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acid} and methods for obtaining them MERCK PATENT GMBH (DE) 2013-11-19 US disclosed
US-20120288539-A1 PHARMACEUTICAL COMPOSITION COMPRISING OLIGOPEPTIDES MERCK PATENT GMBH (DE) 2012-11-15 US disclosed
EP-2509583-A2 PHARMACEUTICAL COMPOSITION COMPRISING OLIGOPEPTIDES, PREFERABLY CILENGITIDE Merck Patent GmbH (DE) 2012-10-17 EP disclosed
EP-2432801-A2 NOVEL SOLID MATERIALS OF {[2S, 5R,8S,11S)-5-BENZYL-11-(3-GUANIDINO-PROPYL)-8-ISOPROPYL-7-METHYL-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAAZA-CYCLOPENTADEC-2-YL]-ACETIC ACID} AND METHODS FOR OBTAINING THEM Merck Patent GmbH (DE) 2012-03-28 EP disclosed
US-20120065142-A1 NOVEL SOLID MATERIALS OF AND METHODS FOR OBTAINING THEM MERCK PATENT GMBH (DE) 2012-03-15 US disclosed
WO-2011069629-A2 PHARMACEUTICAL COMPOSITION COMPRISING OLIGOPEPTIDES MERCK PATENT GMBH (DE) 2011-06-16 WO disclosed
WO-2010133367-A2 NOVEL SOLID MATERIALS OF {[2S, 5R,8S,11S)-5-BENZYL-11-(3-GUANIDINO-PROPYL)-8-ISOPROPYL-7-METHYL-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAAZA-CYCLOPENTADEC-2-YL]-ACETIC ACID} AND METHODS FOR OBTAINING THEM MERCK PATENT GMBH (DE) 2010-11-25 WO disclosed